Loncar Cancer Immunotherapy ETF Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
+0.23 (+0.75 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2,392 shs
Average Volume6,668 shs
Market Capitalization$43.23 million
P/E RatioN/A
Dividend Yield0.94%

Receive CNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for Loncar Cancer Immunotherapy ETF and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer Exchange Traded Concepts
Fund NameLoncar Cancer Immunotherapy ETF
Tax ClassificationRegulated Investment Company
Inception Date10/13/2015
Fund ManagerDenise M. Krisko

Fund Focus

Asset ClassEquity
BenchmarkLoncar Cancer Immunotherapy Index
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$38.23 million
Average Daily Volume$13,681.70

ETF Expenses

Management Fee0.79%
Other Expenses0.00%
Total Expenses0.79%
Fee Waiver0.00%
Net Expenses0.79%

Administrator, Advisor and Custodian

AdministratorU.S. Bancorp Fund Services, LLC
AdvisorExchange Traded Concepts, LLC
CustodianU.S. Bank National Association
DistributorQuasar Distributors, LLC
Transfer AgentU.S. Bancorp Fund Services, LLC
Lead Market MakerJane Street

Geographic Exposure of CNCR

Currency Exposure of CNCR

Sector Exposure of CNCR

Industry Exposure of CNCR

speech bubbles
speech bubbles

Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR) Frequently Asked Questions

What stocks does MarketBeat like better than Loncar Cancer Immunotherapy ETF?

Wall Street analysts have given Loncar Cancer Immunotherapy ETF a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Loncar Cancer Immunotherapy ETF wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Loncar Cancer Immunotherapy ETF?

Loncar Cancer Immunotherapy ETF saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 600 shares, a decrease of 64.7% from the August 15th total of 1,700 shares. Based on an average trading volume of 4,700 shares, the short-interest ratio is currently 0.1 days.
View Loncar Cancer Immunotherapy ETF's Short Interest

How often does Loncar Cancer Immunotherapy ETF pay dividends? What is the dividend yield for Loncar Cancer Immunotherapy ETF?

Loncar Cancer Immunotherapy ETF declared an annual dividend on Tuesday, December 29th. Stockholders of record on Thursday, December 31st will be given a dividend of $0.288 per share on Monday, January 4th. This represents a dividend yield of 0.89%. The ex-dividend date is Wednesday, December 30th.
View Loncar Cancer Immunotherapy ETF's dividend history

Is Loncar Cancer Immunotherapy ETF a good dividend stock?

Loncar Cancer Immunotherapy ETF pays an annual dividend of $0.29 per share and currently has a dividend yield of 0.94%.
View Loncar Cancer Immunotherapy ETF's dividend history.

What other stocks do shareholders of Loncar Cancer Immunotherapy ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Loncar Cancer Immunotherapy ETF investors own include Micron Technology (MU), Intel (INTC), Inovio Pharmaceuticals (INO), Pfizer (PFE), (SNY), Gilead Sciences (GILD), Mastercard (MA), Abbott Laboratories (ABT), Alibaba Group (BABA) and Quest Diagnostics (DGX).

What is Loncar Cancer Immunotherapy ETF's stock symbol?

Loncar Cancer Immunotherapy ETF trades on the NASDAQ under the ticker symbol "CNCR."

Who are Loncar Cancer Immunotherapy ETF's major shareholders?

Loncar Cancer Immunotherapy ETF's stock is owned by many different institutional and retail investors. Top institutional investors include Flow Traders U.S. LLC (2.47%).

Which major investors are buying Loncar Cancer Immunotherapy ETF stock?

CNCR stock was acquired by a variety of institutional investors in the last quarter, including Flow Traders U.S. LLC.

What is Loncar Cancer Immunotherapy ETF's stock price today?

One share of CNCR stock can currently be purchased for approximately $30.88.

How much money does Loncar Cancer Immunotherapy ETF make?

Loncar Cancer Immunotherapy ETF has a market capitalization of $43.23 million.

This page was last updated on 9/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.